We devote an exceptional breadth and depth of clinical trial experience and scientific expertise to our work advancing research in oncology and hematology. From our work on the first-ever development program for a checkpoint inhibitor to designing today’s most innovative cancer clinical trials, our experts dedicated to oncology and hematology – more than 3,500 of us – have a history of embracing bold visions and bringing passion, focus and skill to the business of realizing them.
At Syneos Health, more than 3,500 CRAs, project managers, medical directors and executive leadership are focused solely on oncology and hematology. They bring a wealth of experience and strong site and investigator relationships to ensure the successful delivery of your clinical development plans.
Therapeutic Depth and Expertise
- Monoclonal antibodies, checkpoint inhibitors, vaccines, targeted therapies, gene therapies and adoptive cell transfer technologies
- Precision medicine, investigator-led and cooperative group trials, basket studies and umbrella trials, such as the Leukemia and Lymphoma Society's "Beat AML" Master Trial
Drawing on our depth and breadth of experience, we identify important issues that can otherwise be overlooked during protocol design and study execution such as access to patients for rare disease studies, the challenges of biologic and targeted therapy development, competing studies, trial design complexity/technicality and novel mechanisms of action.
Bridging from Clinical Development to Commercialization
Our oncology and hematology expertise runs deep and also wide – extending beyond clinical development to commercialization of oncology therapeutics:
At Syneos Health, Shortening the Distance from Lab to Life® means that insights across the clinical-commercial continuum are used to help define the most effective, cost-efficient pathway for accelerating oncology drug development and their availability to patients.